ADMET plays an integral role in drug discovery, development, and safety. Predictive ADMET methods are also a necessary step in minimising drug failure. As such, strategies and approaches are constantly evolving, improving, and developing. This conference will draw upon ADMET, Safety, and Translation and encapsulate them in regards to drug discovery and development.
This year's agenda will not only run through in vivo, in vitro, and in silico approaches to ADMET but will also integrate them with an emphasis on clinical implications. Attendees will be at a distinct advantage as they hear from the leading industry experts on themes including Predictive ADME, Screening Approaches, Pre-clinical Screening Approaches, and Predictive Toxicology, emerging issues such as, regulatory changes and Drug-Drug interactions.
KEY REASONS TO ATTEND
Examine how new strategies in ADME impact drug discovery, development, safety; and most importantly the subsequent clinical implications.
Discuss the predictive methods of ADME, pre-clinical translational approaches, the various up-to-datetransporter and screening assays.
Hear the latest on predictive toxicology, genotoxicity, and metabolic toxicity.
Explore emerging issues within the field including Drug-Drug interactions, regulatory guideline changes and the impact on ADME studies.
Register online here: www.smi-online.co.uk/goto/2013admet2.asp
Alternatively Contact Fateja Begum on tel: +44 (0)20 7827 6184 or email her on firstname.lastname@example.org